Investigating KA1 domain-mediated regulation of MARK/PAR1 kinases

研究 KA1 结构域介导的 MARK/PAR1 激酶调节

基本信息

  • 批准号:
    9062868
  • 负责人:
  • 金额:
    $ 5.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-05-01 至 2017-04-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): MARK/PAR1 kinases occupy critical signaling nodes in the development of higher organisms, and have been linked to a plethora of disease states including Autism, Alzheimer's, cancer, and heart disease. The goal of this proposal is to elucidate the structural and functional role of the kinase-associated 1 (KA1) domain, which resides at the C-terminus of MARK/PAR1 and related kinases. This module has recently been shown to interact with both phospholipid and protein ligands, but has also been proposed to provide an autoinhibitory function for the attached kinase domain. Preliminary studies have established that a separately purified KA1 module does bind the MARK1 kinase domain and can inhibit activity in vitro. We hypothesize that kinase autoinhibition is relieved upon binding o the KA1 domain to lipid and/or protein ligands and plan to rigorously assess these features of MARK/PAR1 kinases. The aims of this project are to (i) fully characterize the interaction between the MARK1 kinase and KA1 domains through a battery of structural and biophysical methods and, and (ii) establish a functional role for the KA1 domain in MARK1 activity by in vitro kinetic and in vivo cell-based methods, including determination of whether exposure to lipid or protein ligands of this domain disrupt autoinhibition and activate the kinase. These studies will shed light onto how varied inputs from lipid or protein ligands can lead to kinase regulation, and will provide the groundwork for design of specific allosteric inhibitors of MARK/PAR1 kinases.
 描述(由申请人提供):MARK/PAR 1激酶在高等生物体的发育中占据关键的信号节点,并且已经与包括自闭症、阿尔茨海默氏症、癌症和心脏病在内的多种疾病状态相关联。该提案的目标是阐明激酶相关1(KA 1)结构域的结构和功能作用,该结构域位于MARK/PAR 1和相关激酶的C-末端。该模块最近已被证明与磷脂和蛋白质配体相互作用,但也被提出为所连接的激酶结构域提供自抑制功能。初步研究已经确定,一个单独纯化的KA 1模块结合MARK 1激酶结构域,并能抑制体外活性。我们假设激酶自身抑制在KA 1结构域与脂质和/或蛋白质配体结合后得到缓解,并计划严格评估MARK/PAR 1激酶的这些特征。该项目的目的是(i)通过一系列结构和生物物理方法充分表征MARK 1激酶和KA 1结构域之间的相互作用,以及(ii)通过体外动力学和体内基于细胞的方法确定KA 1结构域在MARK 1活性中的功能作用,包括确定暴露于该结构域的脂质或蛋白质配体是否会破坏自抑制并激活激酶。这些研究将阐明脂质或蛋白质配体的不同输入如何导致激酶调节,并将为设计MARK/PAR 1激酶的特异性变构抑制剂提供基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ryan P. Emptage其他文献

Ryan P. Emptage的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ryan P. Emptage', 18)}}的其他基金

Investigating KA1 domain-mediated regulation of MARK/PAR1 kinases
研究 KA1 结构域介导的 MARK/PAR1 激酶调节
  • 批准号:
    9401848
  • 财政年份:
    2015
  • 资助金额:
    $ 5.61万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 5.61万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 5.61万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 5.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 5.61万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 5.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 5.61万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 5.61万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 5.61万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 5.61万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 5.61万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了